Trials / Completed
CompletedNCT02045472
A Study of VIS410 to Assess Safety and Pharmacokinetics
Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VIS410) to Influenza Type A Hemagglutinin
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Visterra, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacokinetics of single escalating doses of VIS410 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VIS410 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2014-01-24
- Last updated
- 2015-05-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02045472. Inclusion in this directory is not an endorsement.